Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomas.

Nature communications - 16 Aug 2024

Batool Syeda Maheen, Escobedo Ana K, Hsia Tiffaney, Ekanayake Emil, Khanna Sirena K, Gamblin Austin S, Zheng Hui, Skog Johan, Miller Julie J, Stemmer-Rachamimov Anat O, Cahill Daniel P, Balaj Leonora, Carter Bob S

Abstract excerpt

Glioma represents the most common central nervous system neoplasm in adults. Current classification scheme utilizes molecular alterations, particularly IDH1.R132H, to stratify lesions into distinct prognostic groups. Identification of the single nucleotide variant through traditional tissue biopsy assessment poses procedural risks and does not fully reflect the heterogeneous and evolving tumor landscape. Here, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Case-Control Studies

Share to Extracellular Vesicles

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Liquid Biopsy

Share to Sensitivity and Specificity

Source

Open in PubMed Open full text

Identifiers

PMID: 39152110
DOI: 10.1038/s41467-024-51332-7
PMCID: PMC11329733

Genes

IDH1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical utility of a blood based assay for the detection of IDH1.R132H-mutant gliomas.PMID 39152110Read ↗

Clinical utility of plasma cell-free DNA (cfDNA) in diffuse gliomas for the detection of IDH1 R132H mutation.Semantic proximity Read ↗

Analysis of cerebrospinal fluid tumor-derived DNA to obviate biopsy of IDH-mutant brainstem glioma in an adultSemantic proximity Read ↗

Evaluation of the rapid Idylla IDH1-2 mutation assay in FFPE glioma samples.Semantic proximity Read ↗

IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients.Semantic proximity Read ↗

The clinical use of IDH1 and IDH2 mutations in gliomasSemantic proximity Read ↗

Integrated clonal analysis reveals circulating tumor DNA in urine and plasma of glioma patientsSemantic proximity Read ↗

Comprehensive clinical assays for molecular diagnostics of gliomas: the current state and future prospectsSemantic proximity Read ↗

Detection of IDH1 mutation in the plasma of patients with glioma.Semantic proximity Read ↗

Electronic DNA Analysis of CSF Cell-free Tumor DNA to Quantify Multi-gene Molecular Response in Pediatric High-grade Glioma.Semantic proximity Read ↗

Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations.Semantic proximity Read ↗

Detection of H3F3A K27M or BRAF V600E in liquid biopsies of brain tumor patients as diagnostic and monitoring biomarker: impact of tumor localization and sampling method.Semantic proximity Read ↗

Golden rules for optimizing the diagnostic pathway of IDH-mutant tumors: bridging evidence and clinical practice in cholangiocarcinoma and adult-type diffuse gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.